Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
andecaliximab + leucovorin + oxaliplatin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Andecaliximab + leucovorin + oxaliplatin + 5-fluorouracil is an investigational four-drug combination regimen for the treatment of advanced gastrointestinal cancers, particularly gastric and gastroesophageal junction adenocarcinoma. **Andecaliximab** is a recombinant chimeric IgG4 monoclonal antibody that selectively inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in tumor remodeling, growth, and metastasis. **Leucovorin (folinic acid)** acts as a biomodulator to enhance the cytotoxicity of 5-fluorouracil. **Oxaliplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis. **5-fluorouracil (5-FU)** inhibits thymidylate synthase, impairing DNA synthesis and cell division in malignant cells. The regimen is typically administered intravenously and has demonstrated promising antitumor activity and a manageable safety profile in phase I/III clinical trials, especially in patients with HER2-negative advanced gastric or gastroesophageal adenocarcinoma[1][3][5].
- Other names
- ADX + leucovorin + oxaliplatin + 5-FUandecaliximab + mFOLFOX6
02
Targets
DNAMMP9 (Matrix metalloproteinase-9)TS (Thymidylate synthase)
Beyond the preview
Go deeper on andecaliximab + leucovorin + oxaliplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on andecaliximab + leucovorin + oxaliplatin + 5-fluorouracil.